
|Videos|March 30, 2022
Prognostic Value of Biomarkers in RCC
Author(s)Robert S. Alter, MD
Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Withdraws Adagrasib/Cetuximab Approval in KRAS G12C-Mutated CRC
2
FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC
3
Enrollment Begins for Elritercept Phase 3 Trial in Lower-Risk MDS
4
Azacitidine/Venetoclax Boosts Event-Free Survival in Induction-Eligible AML
5





































































